PLATFORM TECHNOLOGY
PIPELINES
Below is the current status of PLABiologics’ stem cell therapy pipelines, based on PLAB’s innovative technology.
| Project | Indication | Status | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
Indication Polycystic ovary syndrome |
Status pre-IND |
preclinical GLP-Tox P1/P2 |
|||||
Indication Macular degeneration |
Status GLP-Tox |
preclinical GLP-Tox P1 |
|||||
Indication Metabolic dysfunction-associated steatohepatitis |
Status preclinical |
preclinical GLP-Tox P1 |
|||||
Indication Diabetic retinopathy |
Status preclinical |
preclinical GLP-Tox P1 |
|||||
UNIPla®
Technology for the isolation and cultivation
of highly purified placental chorionic plate-
derived mesenchymal stem cells.
- The earliest stage of MSCs
- High-purity isolation quickly and easily without mixing of other cells
- Superior proliferative potentials as the earliest stage of MSCs
- No ethical problem.
- Multi-lineage differentiation potentials
- Accessibility to obtain of abundant stem cells.
- Immunosuppressive function
SUNIPla®
Technology for generating
functionally enhanced stem cells
- High safety with non-chromosomal insertion
- High efficiency of gene introduction.
- Stable cell line
- Easy and simple operation.
- Clear mode of action (MoA).
